ANTITUMOR ACTIVITY OF QUINOCARMYCIN AGAINST CARCINOMA OF THE LUNG IN HUMAN TUMOR CLONOGENIC ASSAY
Search this Article
Quinocarmycin monocitrate is a novel antitumor antibiotic isolated from Streptomyces melanovinaceus. We have utilized a human tumor clonogenic assay to test the antitumor activity of this drug against carcinoma of the lung and to compare its activity with those of mitomycin C or cisplatin, which are components of the clinically effective regimens in therapy for this desease. The overall in vitro response rate (defined as less than 50% survival of tumor colony forming units) for quinocarmycin at 0.1 and 1.0 μg/ml continuous exposure was 42% and 72%, respectively, which was superior to that of other drugs. Quinocarmycin and other antitumor drugs do not have identical spectra of antitumor activities in vitro, suggesting that this compound with good in vitro activity should be further developed for clinical trials.
- Journal of pharmacobio-dynamics
Journal of pharmacobio-dynamics 10(9), 431-435, 1987-09
The Pharmaceutical Society of Japan